What is Zelluna Immunotherapy?
Zelluna Immunotherapy is a pioneering biotechnology firm dedicated to creating advanced cell therapies aimed at treating solid cancers. The company's core innovation lies in its proprietary TCR-NK cell therapy platform, designed to address the persistent challenges in effectively treating solid tumors. With a robust intellectual property portfolio and an experienced scientific team, Zelluna is positioned to make substantial contributions to the field of oncology, striving to enhance patient outcomes through cutting-edge immunotherapies.
How much funding has Zelluna Immunotherapy raised?
Zelluna Immunotherapy has raised a total of $14.5M across 2 funding rounds:
Other Financing Round
$8.5M
Other Financing Round
$6M
Other Financing Round (2020): $8.5M, investors not publicly disclosed
Other Financing Round (2020): $6M, investors not publicly disclosed
What's next for Zelluna Immunotherapy?
The substantial enterprise-level financing and recent strategic investment signal a critical growth phase for Zelluna Immunotherapy. This capital infusion is expected to accelerate the development and potential commercialization of its TCR-NK cell therapy platform. The company is likely to focus on expanding its clinical trial pipeline, enhancing manufacturing capabilities, and forging strategic partnerships to broaden its market reach. This strategic backing positions Zelluna to further its mission of transforming cancer care by leveraging the power of the immune system.
See full Zelluna Immunotherapy company page
